Biopharmaceutical company AN2 Therapeutics Inc (Nasdaq: ANTX) announced on Wednesday that it has entered into a strategic collaboration with the Drugs for Neglected Diseases initiative (DNDi) to accelerate the clinical development of AN2-502998, a novel oral drug candidate for chronic Chagas disease.
AN2-502998, an orally active CPSF3 inhibitor from the benzoxaborole class, targets the T. cruzi parasite responsible for Chagas disease. The compound is structurally related to acoziborole, which demonstrated a ~95% cure rate in human African trypanosomiasis. AN2 has initiated Phase 1 startup activities, with completion expected in H2 2025 and a Phase 2 proof-of-concept study planned for 2026.
DNDi, leveraging its extensive clinical trial network across Latin America and Spain, will provide operational and scientific support. The collaboration aims to develop a safer, more effective, and accessible treatment option for the estimated 6–7 million global Chagas patients, including 300,000 in the United States.
No FDA-approved treatments currently exist for adult Chagas patients. This alliance seeks to fill a critical treatment gap for a disease that causes long-term, often silent, damage to the heart and gastrointestinal system, and can result in life-threatening complications in up to 30% of chronically infected individuals.
AN2 Therapeutics and DNDi partner to advance oral therapy for chronic Chagas disease
Opus Genetics partners with Global RDH12 Alliance to advance gene therapy for childhood blindness
Lantern Pharma reports first complete response with LP-284 in heavily pretreated lymphoma patient
DualityBio's HER3 ADC DB-1310 granted US FDA Fast Track Designation
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Orion and Bayer receive EU approval for darolutamide in metastatic hormone-sensitive prostate cancer
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy
CorestemChemon partners with ATG Lifetech to provide next-gen preclinical services
Philips launches ECG AI Marketplace to streamline cardiac diagnostics
Nicox signs licensing deal with Kowa for NCX 470 rights
Citius Oncology prices USD9.0m public offering
Genetic Leap's GL-IL2-138 receives FDA IND clearance
Amphix Bio's AMFX-200 receives US FDA Orphan Drug Designation to treat acute spinal cord injury